Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

NCT04355806 · clinicaltrials.gov ↗

UNKNOWN

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Influenza Vaccine

Interventions

DRUG: PD-1/PD-L1 inhibitors
BIOLOGICAL: Inactivated trivalent influenza vaccine

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Collaborators

[object Object]